Wedbush Comments on Immunome's Q3 Earnings (NASDAQ:IMNM)

Key Points

• Wedbush analysts downgraded their Q3 2025 earnings estimates for Immunome, predicting an earnings per share of ($0.50), down from a previous estimate of ($0.45).
• Immunome reported revenue of $4.02 million for the latest quarter, significantly exceeding the consensus estimate of $1.03 million.
• As of now, Immunome holds a market capitalization of $843.42 million, with shares currently trading around $9.69.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Wedbush reduced their Q3 2025 earnings estimates for Immunome in a research note issued to investors on Thursday, August 7th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.50) per share for the quarter, down from their prior estimate of ($0.45). Wedbush currently has a "Outperform" rating and a $21.00 target price on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome's Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.04) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($0.21) EPS.

IMNM has been the subject of several other reports. JPMorgan Chase & Co. reduced their target price on Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research report on Thursday. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $23.14.

Immunome Stock Performance

Shares of IMNM stock opened at $9.69 on Monday. The company has a market capitalization of $843.42 million, a PE ratio of -3.15 and a beta of 1.93. Immunome has a 52-week low of $5.15 and a 52-week high of $16.73. The business's fifty day moving average is $9.55 and its 200 day moving average is $8.90.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime acquired 5,000 shares of Immunome stock in a transaction dated Tuesday, June 3rd. The shares were purchased at an average cost of $9.38 per share, for a total transaction of $46,900.00. Following the transaction, the director owned 36,415 shares of the company's stock, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.69% of the stock is currently owned by company insiders.

Institutional Trading of Immunome

A number of hedge funds have recently bought and sold shares of IMNM. Teacher Retirement System of Texas raised its stake in shares of Immunome by 6.8% during the second quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company's stock worth $172,000 after acquiring an additional 1,188 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Immunome by 3.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company's stock valued at $470,000 after purchasing an additional 1,643 shares during the last quarter. Invesco Ltd. raised its position in Immunome by 6.4% in the 1st quarter. Invesco Ltd. now owns 28,379 shares of the company's stock worth $191,000 after purchasing an additional 1,718 shares during the period. Voya Investment Management LLC lifted its stake in Immunome by 21.2% in the first quarter. Voya Investment Management LLC now owns 18,905 shares of the company's stock worth $127,000 after purchasing an additional 3,305 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock worth $1,546,000 after purchasing an additional 4,874 shares during the last quarter. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.